New fund: SV Life Sciences raising $400M for biotech, health IT startups
The venture capital firm's last fund, in 2010, raised $523M. Historically, SV Life Sciences has invested about 40 percent of its funds in later-stage deals.
Versant Ventures seeks $250M for next medtech venture capital fund
Though lots of venture capital for medtech has evaporated, Versant Ventures now seeks $250 million for its fifth medtech fund. The venture capital firm, which has strong presence in biotech and medtech, has a diverse California and Minnesota-based portfolio that includes medical device companies such as Respicardia, Zyga Technology and Autonomic Technologies. According to a […]
presented by
When Investment Rhymes with Canada
Canada has a proud history of achievement in the areas of science and technology, and the field of biomanufacturing and life sciences is no exception.
These are the most active VCs in healthcare since 2012
As investments in life science companies have dipped over the past few years, some investors have scaled back investments or walked away from the sector all together. But based on a tally by investment research firm PitchBook in its 2013 Venture Capital Healthcare Report, several firms have made 10 or more investments in pharmaceutical, medical […]
FDA regulations will send medical device companies out of US, VC warns
Healthcare venture capital executive Paul LaViolette warns that an "inefficient and unpredictable regulatory system" at the Food & Drug Administration should have government officials worrying "more about losing firms to Costa Rica than California. One of LaViolette's killer statistics: three-quarters of the cost to bring new innovative medical devices to market in the United States is in dealing with regulatory issues.
SV Life Sciences beats target with $523M fund
SV Life Sciences has raised the year’s second-largest life sciences fund thus far, exceeding its targeted amount to close with $523 million in commitments. The firm had originally planned to raise $400 million, but attributed its fundraising success in today’s “challenging environment” to its past success, according to a statement. SV’s fundraise represents the second-largest […]
Ricerca Biosciences agrees to buy drug discovery, development unit from MDS Pharma Services
Contract drug development organization Ricerca Biosciences LLC has agreed to acquire the discovery and preclinical business of MDS Pharma Services for $35 million less working capital and cap-ex reserve.
